Dexamethasone: A Comprehensive Overview of a Potent Corticosteroid > 공지사항

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Dexamethasone is a synthetic corticosteroid that has been a cornerstone of anti-inflammatory and immunosuppressive therapy for decades. It belongs to the glucocorticoid class, which mimics the action of natural hormones produced by the adrenal cortex. With a potency approximately 25 times that of cortisol (the primary human glucocorticoid), dexamethasone exerts profound effects on metabolism, immune function, and inflammation. Its long duration of action and minimal mineralocorticoid activity make it particularly useful for conditions requiring sustained suppression of inflammation without significant salt retention. This report provides a brief yet comprehensive overview of dexamethasone, covering its pharmacology, clinical applications, adverse effects, and notable role in the COVID-19 pandemic.

Pharmacology and Mechanism of Action

Dexamethasone acts by binding to the intracellular glucocorticoid receptor (GR), a ligand-activated transcription factor. Upon binding, the receptor-ligand complex translocates to the nucleus and modulates gene expression by interacting with glucocorticoid response elements (GREs) in the DNA. This results in upregulation of anti-inflammatory proteins (e.g., lipocortin-1, which inhibits phospholipase A2, and IκBα, which suppresses NF-κB activity) and downregulation of pro-inflammatory mediators (e.g., cytokines like IL-1, IL-6, TNF-α, and enzymes such as cyclooxygenase-2). The net effect is a broad inhibition of the inflammatory cascade, including reduced vasodilation, decreased capillary permeability, and attenuation of leukocyte migration to sites of injury. Dexamethasone also suppresses the immune system by reducing T-cell proliferation and antibody production, making it valuable in autoimmune and allergic disorders.

Clinical Indications

Dexamethasone has a wide range of therapeutic uses across multiple medical specialties:

• Respiratory Conditions: In severe asthma exacerbations and chronic obstructive pulmonary disease (COPD) with eosinophilic phenotype, dexamethasone reduces airway inflammation. It is also used for croup (laryngotracheobronchitis) in children, typically as a single oral dose to decrease laryngeal edema and stridor.


• Allergy and Immunology: For acute allergic reactions, angioedema, and anaphylaxis adjunctive therapy, 2.5mg - Ballyes.es, dexamethasone prevents late-phase reactions. It is also employed in severe atopic dermatitis, contact dermatitis, and urticaria refractory to antihistamines.


• Rheumatology: As a potent anti-inflammatory, it can be used short-term for acute flares of rheumatoid arthritis, gout, or systemic lupus erythematosus, though chronic use is avoided due to toxicity.


• Oncology: Dexamethasone is widely used as an antiemetic to prevent nausea and vomiting from chemotherapy (especially with highly emetogenic agents), and to manage cerebral edema in brain tumors by reducing peritumoral swelling. It is also part of combination chemotherapy regimens (e.g., in multiple myeloma, lymphomas) to potentiate cell kill and treat hypercalcemia of malignancy.


• Endocrinology: In congenital adrenal hyperplasia, dexamethasone suppresses excessive ACTH production from the pituitary, reducing androgen excess. It is used in the diagnostic dexamethasone suppression test for Cushing’s syndrome.


• Ophthalmology: Topical or systemic dexamethasone treats non-infectious uveitis, macular edema, and post-operative inflammation after cataract surgery.


• COVID-19 Pandemic: This application deserves special mention. In 2020, the RECOVERY trial demonstrated that dexamethasone (6 mg once daily for up to 10 days) significantly reduced 28-day mortality in hospitalized patients with COVID-19 who required oxygen or mechanical ventilation. The benefit was most pronounced in those needing invasive ventilation (mortality reduction of about one-third) and less in those receiving oxygen (one-fifth), while no benefit was seen in patients not requiring respiratory support. This effect is attributed to dexamethasone’s ability to dampen the hyperinflammatory "cytokine storm" that drives acute respiratory distress syndrome (ARDS) in severe COVID-19.

Dexamethasone is available in oral tablets (0.5 mg, 0.75 mg, 1.5 mg, 4 mg, 6 mg), oral solution, injectable forms (4 mg/mL, 20 mg/5 mL), and topical preparations (ophthalmic drops, creams). Dosing varies widely by indication. For acute conditions, a typical starting oral dose is 0.75–9 mg per day, often divided into two to four doses, though for maintenance, once daily dosing is common due to its long half-life (36–54 hours). Intravenous or intramuscular administration is reserved for emergencies like anaphylaxis, cerebral edema, or severe COVID-19 (6 mg IV daily). In neonates, dexamethasone is sometimes used for ventilator dependency, but with caution due to neurodevelopmental risks.

Adverse Effects and Precautions

Despite its therapeutic power, dexamethasone carries significant risks, especially with prolonged use. Common side effects include weight gain, central obesity (moon facies, buffalo hump), hyperglycemia (diabetes exacerbation), hypertension, osteoporosis, proximal myopathy, increased appetite, insomnia, and mood disturbances (from euphoria to depression). Long-term therapy suppresses the hypothalamic-pituitary-adrenal (HPA) axis, necessitating slow tapering to avoid adrenal insufficiency. Other concerns include peptic ulcer risk, impaired wound healing, increased susceptibility to infections (including reactivation of tuberculosis, hepatitis B, and herpes zoster), cataracts, and glaucoma with ocular use. In children, growth retardation is a major concern.

Contraindications include systemic fungal infections, known hypersensitivity, and use of live vaccines. Caution is warranted in patients with diabetes, hypertension, congestive heart failure, osteoporosis, glaucoma, and peptic ulcer disease. Drug interactions are numerous: nonsteroidal anti-inflammatory drugs increase ulcer risk; anticoagulants may have altered effect; insulin/oral hypoglycemics may require dose adjustment; and enzyme inducers (e.g., rifampin, carbamazepine) reduce dexamethasone efficacy.

Conclusion

Dexamethasone remains one of the most potent and versatile corticosteroids in modern medicine. Its ability to suppress inflammation and modulate immunity makes it invaluable across a broad spectrum of acute and chronic conditions, from asthma and allergies to cancer and severe infections like COVID-19. However, its use demands careful risk–benefit analysis, particularly concerning long-term adverse effects and HPA axis suppression. Ongoing research continues to explore optimal dosing strategies, especially in pandemic settings, and novel formulations such as sustained-release implants for ophthalmic disease. When used judiciously, dexamethasone saves countless lives and improves quality of life, but it must always be prescribed with vigilance and respect for its powerful pharmacological profile.